Examples of using Interaction study in English and their translations into Romanian
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Programming
No interaction study performed.
Interaction study performed only with ritonavir.
Bedaquiline No interaction study is available with ritonavir only.
No interaction study has been performed with antibiotics, ergot alkaloids, and anti-hypertensive agents other than labetalol.
No clinical interaction study was performed with a substrate of CYP 2C8.
This interaction study has been performed with a dose higher than the recommended dose for rilpivirine.
No drug-drug interaction study has been conducted with cardiac glycosides and Natpar(see section 4.4).
A Phase 1 interaction study evaluated the effect of cigarette smoking(CYP1A2 inducer) on the pharmacokinetics of Esbriet.
An in vivo interaction study with warfarin indicated that rosiglitazone does not interact with CYP2C9 substrates in vivo.
In an interaction study, the mean doripenem AUC increased by 75% following co-administration with probenecid.
This interaction study has been performed with a dose higher than the recommended dose for rilpivirine assessing the maximal effect.
In an interaction study of single-dose bedaquiline and multiple dose lopinavir/ritonavir, the AUC of bedaquiline was increased by 22%.
In a drug interaction study with single-dose warfarin administration, there was a significant increase in the mean AUC(+57%) of S-warfarin.
No interaction study between Xeplion and lithium has been performed, however, a pharmacokinetic interaction is not likely to occur.
In an interaction study, Prolia did not affect the pharmacokinetics of midazolam, which is metabolized by cytochrome P450 3A4(CYP3A4).
Based on an interaction study with lopinavir/ ritonavir, combination of rosuvastatin and protease inhibitors is not recommended.
An interaction study with protein-conjugated vaccine against Neisseria menigitidis serogroup C has been investigated in children aged 2-11 years.
No interaction study between INVEGA and lithium has been performed, however, a pharmacokinetic interaction is unlikely to occur.
In a interaction study with single-dose warfarin administration, there was a significant increase in the mean AUC(+57%) of S-warfarin.
An in vivo interaction study with cimetidine(non-specific cytochrome P450 inhibitor) has demonstrated a lack of a significant interaction. .
In an interaction study in healthy volunteers, Cholestagel reduced the AUC and Cmax of levothyroxine when administered either concomitantly or after 1 hour.
An interaction study with carbamazepine does not indicate a marked inhibitory effect of lacosamide on CYP3A4 catalysed metabolism at therapeutic doses.
In an interaction study of single-dose bedaquiline and multiple-dose lopinavir/ritonavir, exposure(AUC) to bedaquiline was increased by 22%[90% CI(11; 34)].
This interaction study has been performed with a dose higher than the recommended dose for rilpivirine hydrochloride assessing the maximal effect on the co-administered medicinal product.
This interaction study has been performed with a dose higher than the recommended dose for rilpivirine hydrochloride assessing the maximal effect on the co-administered medicinal product.
In an interaction study, the serum concentrations of valproic acid were markedly reduced(AUC was reduced by 63%) following co-administration of doripenem and valproic acid.
In an interaction study in healthy volunteers, co-administration of Cholestagel and ciclosporin significantly reduced the AUC0-inf and Cmax of ciclosporin by 34% by 44%, respectively.
An in vivo interaction study with leflunomide and cimetidine(non-specific weak cytochrome P450(CYP) inhibitor) has demonstrated a lack of a significant impact on A771726 exposure.
An interaction study in women between APTIVUS, co-administered with low dose ritonavir, and ethinyl oestradiol/ norethindrone demonstrated a high frequency of non-serious rash.
An interaction study based on data from 12 patients, assessing the effect of ketoconazole, a potent CYP3A4 inhibitor, showed a bortezomib AUC mean increase of 35%(CI90%[1.032 to 1.772]).